Recently, the National Healthcare Security Administration and the National Health Commission have jointly unveiled a document outlining 16 specific measures to bolster the advancement of innovative drugs. These measures encompass vital aspects including research and development, market entry, payment management, and clinical application. The aim of these policies is to elevate the efficiency of innovative drug R&D in China, expedite market access, and bolster commercial return capabilities. It is anticipated that from 2024 to 2025, the innovative drug industry will embrace a period of policy-driven benefits, fostering its high-quality development and further solidifying China's position in the global innovative drug market. In response to the positive impact of this policy, innovative drug stocks listed in Hong Kong have generally witnessed an upswing, with Hua Hao Zhongtian Pharmaceuticals leading the charge, recording a remarkable 23% increase in just three days, effectively doubling its gains.